Bipartisan Senators Seek Answers on Gilead's Expensive Hep C Drug Sovaldi

Drug Industry Daily
The price of Gilead’s hepatitis C drug Sovaldi once again is drawing bipartisan fire from Capitol Hill, this time from two senators who are demanding answers as to how the company arrived at the product’s $1,000-a-pill price tag.

To View This Article:


Subscribe To Drug Industry Daily